Ingalls & Snyder LLC trimmed its stake in shares of Omeros Co. (NASDAQ:OMER) by 1.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,077,257 shares of the biopharmaceutical company’s stock after selling 93,150 shares during the quarter. Omeros accounts for 4.2% of Ingalls & Snyder LLC’s portfolio, making the stock its 3rd largest holding. Ingalls & Snyder LLC owned approximately 10.36% of Omeros worth $88,192,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in shares of Omeros by 73.3% in the fourth quarter. Rhumbline Advisers now owns 72,243 shares of the biopharmaceutical company’s stock valued at $805,000 after acquiring an additional 30,547 shares during the last quarter. Man Group plc bought a new position in shares of Omeros in the third quarter valued at approximately $286,000. Miramar Capital LLC bought a new position in shares of Omeros in the fourth quarter valued at approximately $192,000. Sheaff Brock Investment Advisors LLC raised its stake in shares of Omeros by 8.8% in the fourth quarter. Sheaff Brock Investment Advisors LLC now owns 24,750 shares of the biopharmaceutical company’s stock valued at $276,000 after acquiring an additional 2,000 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. raised its stake in shares of Omeros by 49.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,912,244 shares of the biopharmaceutical company’s stock valued at $21,303,000 after acquiring an additional 632,840 shares during the last quarter. 49.19% of the stock is currently owned by institutional investors.
OMER stock traded up $0.14 during trading on Thursday, hitting $18.06. The company had a trading volume of 268,974 shares, compared to its average volume of 644,075. Omeros Co. has a 12 month low of $10.30 and a 12 month high of $27.00. The stock has a market capitalization of $878.26 million, a PE ratio of -8.14 and a beta of 3.60.
A number of research analysts have recently issued reports on the stock. ValuEngine upgraded shares of Omeros from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, April 3rd. Zacks Investment Research upgraded shares of Omeros from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Thursday, March 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Omeros in a research note on Monday, March 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $27.00.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Recommended Story: Consumer Price Index (CPI)
Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Co. (NASDAQ:OMER).
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.